Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Non-randomized Phase 1, Multicenter Study to Assess Radium-223 Biodistribution in Participants With Bone Metastatic Castration Resistant Prostate Cancer (CRPC) Receiving Radium-223 Dichloride Treatment.

NCT04521361 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT04521361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04521361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Non-randomized Phase 1, Multicenter Study to Assess Radium-223 Biodistribution in Participants With Bone Metastatic Castration Resistant Prostate Cancer (CRPC) Receiving Radium-223 Dichloride Treatment.
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
November 16, 2020
Completion date
August 27, 2025
Enrollment
46 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastatic castration-resistant prostate cancer